Af­ter show­ing We­govy cut car­dio­vas­cu­lar risk by 20%, re­sults de­tail im­pact on death and heart fail­ure

Three months af­ter a large study of No­vo Nordisk’s pop­u­lar weight-loss and di­a­betes in­jec­tion showed it cut ma­jor car­dio­vas­cu­lar risks by 20%, fur­ther re­sults from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.